The Morning: The promise of Ozempic

Plus, a shooting in Russia, abortion and male kindergarten teachers.

View in browser|nytimes.com June 24, 2024 Good morning. Today, my colleague Dani Blum writes about the intriguing promise of drugs like Ozempic. We're also covering a shooting in Russia, abortion and male kindergarten teachers. —David Leonhardt A woman injects a dose of Wegovy. Cydni Elledge for The New York Times The new panacea? By Dani Blum I've covered Ozempic and similar drugs since 2022. In the past two years, Ozempic has become a synonym for weight loss. When celebrities slimmed down, tabloids wondered whether they were taking the drug. Activists argued that the drug entrenched old norms about body image — people still seemed to want to be thin. Ozempic was weight loss; weight loss was Ozempic. It's like Kleenex or Scotch tape: totemic. Technically, while Ozempic is a diabetes drug, people can, and do, take it to drop weight. But the drug — and others in its class, such as Wegovy, Mounjaro and Zepbound — is about much more. Scientists believe the drugs are about to revolutionize several fields of medicine, such as cardiology and endocrinology. Researchers are also running dozens of trials to see whether they might help with Alzheimer's, liver disease, polycystic ovary syndrome and even skin conditions. If these trials prove successful, the drugs may extend many lives by years, save billions in medical costs and divide public health into before-and-after epochs. A researcher studying these drugs told me he felt like the scientist who first discovered antibiotics. Those are some sky-high hopes, and not all will be come true. But we've already seen a real-world impact. In March, the Food and Drug Administration said that doctors could use Wegovy to reduce the risk of heart problems. Last month, a trial showed that the compound in Ozempic reduced the risk of complications from chronic kidney disease. And last week, two trials found that tirzepatide, the substance in Mounjaro and Zepbound, could improve symptoms of sleep apnea. The idea that a single drug that could target so many kinds of disease might sound too good to be true. These drugs, called GLP-1s (glucagon-like peptide 1 receptor agonists), mystify even the scientists who study them. When I asked researchers how it was possible that Ozempic might help with cognitive issues and nonalcoholic fatty liver disease and opioid addiction, they gave the same answer: We don't know! But we have early clues about where these drugs might take us — and what that means for medicine. In today's newsletter, I'll explain. Ozempic injection pens on the production line. Charlotte de la Fuente for The New York Times Fighting inflammation Some researchers think Ozempic and drugs like it may have something of a medical superpower: lowering inflammation in the body. Inflammation is a key part of the body's defense system. When we sense a threat, such as one posed by a pathogen, our cells work to help us fight off the intruder. But chronic inflammation contributes to heart disease, lung disease, diabetes and a host of other major illnesses. If new obesity drugs really do reduce inflammation, that could explain their effect across such a wide spectrum of diseases. Still, there are already limits. Not everyone responds to GLP-1s. Even those who slim down inevitably hit a floor, typically after losing about 15 percent of their body weight. And the drugs come with side effects (nausea, vomiting, diarrhea and constipation) and rare but serious risks: People can develop gallstones and an inflamed pancreas; they can eat so little they become malnourished; and, more commonly, they can lose muscle mass. Limiting urges We know that these medications target the areas of the brain that regulate appetite. But there are questions around what else the drugs do to the mind. I've interviewed dozens of people taking these medications who say they've lost all interest in alcohol. Could these drugs curb other compulsive behavior, too, the way they silence "food noise"? Studies in rats suggest that GLP-1s reduce cravings for cocaine. Scientists are examining whether these medications might even be able to alleviate gambling addictions and smoking. The great experiment Ozempic and drugs like it are considered "forever drugs" — that is, people are supposed to stay on them for the rest of their lives. They're like statins or blood pressure medications. When you stop taking them, they stop working. A display at a GNC store. Maansi Srivastava/The New York Times But this class of drugs has existed for less than 20 years. Ozempic itself has been on the market for only six. We don't know what happens after lifelong use of these drugs. Researchers point to past examples of drugs we once thought were miraculous, chiefly fen-phen. It, too, was astonishingly effective for weight loss. Then doctors learned that it damaged the heart and stopped prescribing it. It will take years, more diverse trials and much more data to determine the potential of these drugs. We are years away from solid evidence underpinning their use to treat Alzheimer's disease, for instance. There's a chance they won't do what scientists hope. Researchers sometimes tell me that we're living through the great Ozempic experiment. Hundreds of thousands of people across the globe are taking GLP-1s. The number will rise as they're approved for other uses. It may be years or generations before we know their hidden limitations — or their full powers. For more We know where the new weight-loss drugs come from — but not why they work. These medicines are incredibly expensive. One state stopped covering some of them this year. ADVERTISEMENT THE LATEST NEWS Russia Shootings Law enforcement in images released by Russian authorities.  National Antiterrorism Committee, via Reuters Gunmen attacked synagogues and churches in two cities in southern Russia. They used rifles and Molotov cocktails. The attackers killed police officers and a priest. Six of the gunmen died in shootouts, officials said. While the attacks appeared coordinated, the Russian authorities have not yet identified the gunmen or offered a possible motive. Israel-Hamas War Benjamin Netanyahu, in a television interview, said that the intensive phase of Israel's war against Hamas would soon end. Israel bombed a U.N. compound near Gaza City, killing at least eight people, a Palestinian news agency said. The Israeli military said militants were using the compound, which Hamas has denied. Many people in southern Israel, still reeling from the Oct. 7 attacks, blame Hamas for the suffering in Gaza and struggle to sympathize. The Manhattan district attorney declined to prosecute most of the protesters charged with taking over a Columbia University hall, citing a lack of evidence. More International News Pilgrims shield themselves from the sun. Fadel Senna/Agence France-Presse — Getty Images More than 1,300 people have died during the hajj, the Islamic pilgrimage, in Saudi Arabia's heat. The temperature there recently passed 120 degrees. Explosions set a lithium battery factory on fire in South Korea, killing at least 16 people. Many countries in Africa resent France, a former colonial power. Not Rwanda: It is embracing French culture and courting French investment. With a general election next week, support for Britain's governing Conservative Party is collapsing. These charts show why. Ukrainians marked midsummer with festivals, folk dancing and flowers, despite wartime restrictions, The A.P. reports. Abortion This week is the anniversary of the Supreme Court's reversal of Roe v. Wade. In ads and campaign events, Democrats will highlight Donald Trump's role in ending the constitutional right to abortion. The public conversation about abortion has become increasingly focused on pregnancy complications. Politics Michael Flynn, the former national security adviser, has turned his Trump-world celebrity status into a family business that deals in conspiracy theories. Trump, in an address to an evangelical group, said he'd suggested starting a sports league in which migrants fight one another. CNN has sole discretion over the look and cadence of Thursday's presidential debate. In past years, an independent commission had oversight. Other Big Stories The heat wave that broke records in many parts of the U.S. is expected to subside today. After floods hit homes and farmland, the Midwest is strengthening levee systems. Opinions The gay marriage campaign changed the law. But it didn't change many people's minds, Omar Encarnación argues. Voters need politicians' medical information to make informed choices, Dr. Daniela Lamas argues. Here are columns by Maureen Dowd on Sean Penn and David French on Clarence Thomas. Games for relaxation. Games for concentration. We have them all. For a limited time, save 50% on your first year of a New York Times Games subscription and enjoy new puzzles every day. MORNING READS In Wynne, Ark. Whitten Sabbatini for The New York Times Role models: Boys are struggling in education. Male kindergarten teachers can help. Community: Social media is a valuable resource for gay women who come out later in life. Solstice: When the seasons turn, Stonehenge lets visitors celebrate up close. Supplements: Is fish oil helpful or harmful for the heart? Secret beaches: Cap Ferret, on France's western coast, is Paris's answer to Montauk. Locals shared some favorite spots. Metropolitan Diary: Cashing in the tattoo fund. Lives Lived: Silvano Marchetto's Greenwich Village trattoria, Da Silvano, became a star-studded canteen and a Page Six fixture over four decades. He died at 77. SPORTS W.N.B.A.: Angel Reese recorded her eighth straight double-double in the Chicago Sky's big win over Caitlin Clark and the Indiana Fever. Soccer: The U.S. men's team defeated Bolivia, 2-0, in its first game of this year's Copa América. The captain, Christian Pulisic, scored one goal and assisted on the other. N.H.L.: The Oilers and Panthers play tonight in Game 7 of the Stanley Cup Final. ADVERTISEMENT ARTS AND IDEAS Simbarashe Cha/The New York Times How high are your socks? It's an intergenerational debate. Fashion-minded Gen Z-ers have declared a preference for crew socks, which generally rise midway up the shin, and thumbed their noses at the low-rise socks that were staples of the Millennial wardrobe. "I think part of growing up is people trying to separate themselves from what came before them," said Night Noroña, 18, who recently threw away all of his socks that hit below the ankle. Related: Want to buy taller socks? See our favorite pairs. More on culture Taylor Swift and Travis Kelce in London. Gareth Cattermole/Getty Images for TAS Rights Management Taylor Swift brought her boyfriend, Travis Kelce, onstage in London, the BBC writes. (His mom posted about it on Facebook, Us Weekly reports.) The San Francisco Symphony's music director is leaving over budget cuts. It's evidence of the difficulties facing American classical music. How short is too short for a skirt? The Times fashion critic Vanessa Friedman offers some advice. A celebrity-driven trend for "healing" crystals has created a risky mining rush in rural South Africa, The Wall Street Journal reports. THE MORNING RECOMMENDS … Julia Gartland for The New York Times. Pick a few ingredients off this list — maybe olives and anchovies — for a simple puttanesca. Ease your back pain by taking a walk. Resist this cute but disappointing viral oven. Take our news quiz. GAMES Here is today's Spelling Bee. Yesterday's pangram was buoyant. And here are today's Mini Crossword, Wordle, Sudoku, Connections and Strands. Thanks for spending part of your morning with The Times. See you tomorrow. Sign up here to get this newsletter in your inbox. Reach our team at themorning@nytimes.com. Editor: David Leonhardt Deputy Editor: Adam B. Kushner News Editor: Tom Wright-Piersanti Associate Editor: Lauren Jackson News Staff: Desiree Ibekwe, Sean Kawasaki-Culligan, Brent Lewis, German Lopez, Ian Prasad Philbrick, Ashley Wu News Assistant: Lyna Bentahar Saturday Writer: Melissa Kirsch Need help? Review our newsletter help page or contact us for assistance. You received this email because you signed up for the Morning newsletter from The New York Times, or as part of your New York Times account. To stop receiving The Morning, unsubscribe. To opt out of other promotional emails from The Times, including those regarding The Athletic, manage your email settings. To opt out of updates and offers sent from The Athletic, submit a request. Subscribe to The TimesGet The New York Times app Connect with us on: Change Your EmailPrivacy PolicyContact UsCalifornia Notices The New York Times Company. 620 Eighth Avenue New York, NY 10018